<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-L3O3MPDE</identifier><date>2020</date><creator>Grosek, Jan</creator><creator>Omejc, Mirko</creator><creator>Tuta, Mojca</creator><creator>Velenik, Vaneja</creator><creator>Zadnik, Vesna</creator><relation>documents/doc/L/URN_NBN_SI_doc-L3O3MPDE_001.pdf</relation><relation>documents/doc/L/URN_NBN_SI_doc-L3O3MPDE_001.txt</relation><format format_type="issue">4</format><format format_type="volume">54</format><format format_type="type">article</format><format format_type="extent">str. 461-469, IX</format><identifier identifier_type="DOI">10.2478/raon-2020-0043</identifier><identifier identifier_type="ISSN">1318-2099</identifier><identifier identifier_type="COBISSID">24315907</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-L3O3MPDE</identifier><language>eng</language><publisher>Association of Radiology and Oncology</publisher><source>Radiology and oncology (Ljubljana)</source><rights>BY</rights><subject language_type_id="slv">bevacizumab</subject><subject language_type_id="slv">danka</subject><subject language_type_id="slv">kemoradioterapija</subject><subject language_type_id="slv">radiološko zdravljenje</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="slv">zdravljenje</subject><title>a prospective phase II CRAB trial</title><title>Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer</title></Record>